Oxford Biomedica PLC REPLACEMENT: Total Voting Rights (7685X)
May 01 2019 - 6:52AM
UK Regulatory
TIDMOXB
RNS Number : 7685X
Oxford Biomedica PLC
01 May 2019
Oxford Biomedica
Total Voting Rights
The 'Total Voting Rights' announcement released today at 11:33
under RNS No 7565X contained an incorrect figure and is replaced by
this announcement.
Oxford, UK - 1 May 2019: Oxford Biomedica plc ("Oxford
Biomedica" or "the Company") (LSE: OXB), announces that in
accordance with the FCA's Disclosure Guidance and Transparency Rule
5.6.1, the Company's issued share capital as at the close of
business on 30 April 2019 consisted of 68,863,354 ordinary shares
of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares
held in treasury.
Accordingly, the total number of voting rights in Oxford
Biomedica plc at the date of this notice is 68,863,354.
The above figure (68,863,354) may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, Oxford Biomedica plc under the FCA's Disclosure and
Transparency Rules.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Stuart Paynter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK
Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations,
through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than
430 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRCKDDQDBKDCPK
(END) Dow Jones Newswires
May 01, 2019 07:52 ET (11:52 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024